Skip to main content


Front. Pharmacol., 29 January 2020
Sec. Pharmacology of Anti-Cancer Drugs
This article is part of the Research Topic Multi-targeted Natural Products as Cancer Therapeutics: Challenges and Opportunities, Volume I View all 54 articles

RETRACTED: Berberine Maintains the Neutrophil N1 Phenotype to Reverse Cancer Cell Resistance to Doxorubicin

Shuhui Zhang&#x;Shuhui Zhang1†Lin Zhou&#x;Lin Zhou1†Mengdi ZhangMengdi Zhang1Yuehua WangYuehua Wang1Mengqi WangMengqi Wang1Jincheng Du,Jincheng Du1,3Wenwen GuWenwen Gu1Fuguang KuiFuguang Kui1Jiahuan Li*Jiahuan Li1*Shengnan Geng*Shengnan Geng2*Gangjun Du,*Gangjun Du1,2*
  • 1Institute of Pharmacy, Pharmaceutical College of Henan University, Kaifeng, China
  • 2School of Pharmacy and Chemical Engineering, Zhengzhou University of Industry Technology, Xinzheng, China
  • 3Chinese Medical School, Hunan University of Chinese Medicine, Changsha, China

Keywords: berberine, doxorubicin, neutrophil phenotype, carcinogenesis, chemotherapeutic resistance

Citation: Zhang S, Zhou L, Zhang M, Wang Y, Wang M, Du J, Gu W, Kui F, Li J, Geng S and Du G (2020) Berberine Maintains the Neutrophil N1 Phenotype to Reverse Cancer Cell Resistance to Doxorubicin. Front. Pharmacol. 10:1658. doi: 10.3389/fphar.2019.01658

Received: 06 November 2019; Accepted: 17 December 2019;
Published: 29 January 2020; Retracted: 07 December 2023.

Edited by:

Jiangjiang Qin, Zhejiang Chinese Medical University, China

Reviewed by:

Dan Shao, South China University of Technology, China
Qiao Liu, Shandong University, China

These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.